All News

Sexual activity and vaginal dilation could make follow-up examinations more “tolerable” and “pain free” for survivors of cervical cancer after radiotherapy.

Who knew how impactful socks could be!

Prostatic urethra length may help predict which patients with prostate cancer are more likely to experience chronic urinary side effects after radiation treatment, according to a recent study.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

The Food and Drug Administration approved Loqtorzi with and without chemotherapy for certain patients with nasopharyngeal carcinoma.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, explained the impact early satiety can have on patients with MPNs and why communication with their care team is important.

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

A recent phase 2 study showed promising survival improvements with neoadjuvant Libtayo in patients with cutaneous squamous cell carcinoma after a year and a half follow up.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

The Food and Drug Administration accepted an Investigational New Drug application for MB-109, a novel agent that combines two mechanisms to treat recurrent glioblastoma and high-grade astrocytroma.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

It’s key for patients with MPN-related fatigue to communicate changes they feel, especially as they “know their bodies very well,” a nurse told CURE®.

Life after an oophorectomy isn't easy.

As Georgetown women’s basketball couch Tasha Butts died from cancer and “The Walking Dead” actor Erik Jensen revealed cancer diagnosis, here is what’s happening in the oncology space this week.

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

There are three types of myeloproliferative neoplasms, all of which come with their own set of symptoms and management strategies.

Most patients with prostate cancer live full lives after being diagnosed, so it is essential to consider potential long-term effects before choosing a treatment regimen, an expert said.

Breast cancer survivors may experience medium to high symptom burden five or more years after receiving a diagnosis, according to a recent study.

I had the wrong interpretation of what a cancer survivor was. That was until I was diagnosed with a rare cancer and shockingly, the term “cancer survivor” became a part of my journey.

Balversa improved outcomes for patients with high-risk bladder cancer, but may only work for those with a certain genetic alteration, an expert explained.

After the fear of my cancer diagnosis subsided, I decided to swing at it with all my strength.

In this on-demand webinar series, CURE partnered with Look Good Feel Better to demonstrate makeup techniques in applying foundation and blush to combat appearance-related side effect from cancer treatment.

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Excellent adherence to hormonal therapy among patients with ductal carcinoma in situ plays a key role in reducing risk of future tumors, researchers found.

In a recent study, obesity was linked to an increased risk of recurrence for patients with HR-positive, early-stage breast cancer.

Braving the storm that is cancer.

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.